2019
Personalizing Treatment Selection for Breast Cancer
Pusztai L, Yeoh C. Personalizing Treatment Selection for Breast Cancer. 2019, 297-324. DOI: 10.1201/9780429066504-14.Peer-Reviewed Original ResearchBreast cancerTreatment selectionClinical outcomesRisk of recurrenceMultiple treatment optionsParticular clinical outcomesCurrent treatment modalitiesCancer-related deathMore effective treatmentsProbability of benefitBreast cancer researchUnited States FoodSurgical resectionProbability of responseTrastuzumab therapyCommon malignancyTreatment optionsClinicopathologic variablesPatient preferencesSpecific therapyTreatment modalitiesMulti-gene testsDisease outcomeMolecular differencesEffective treatment
2018
An integrative bioinformatics approach reveals coding and non-coding gene variants associated with gene expression profiles and outcome in breast cancer molecular subtypes
Győrffy B, Pongor L, Bottai G, Li X, Budczies J, Szabó A, Hatzis C, Pusztai L, Santarpia L. An integrative bioinformatics approach reveals coding and non-coding gene variants associated with gene expression profiles and outcome in breast cancer molecular subtypes. British Journal Of Cancer 2018, 118: 1107-1114. PMID: 29559730, PMCID: PMC5931099, DOI: 10.1038/s41416-018-0030-0.Peer-Reviewed Original ResearchConceptsHER2-negative tumorsBreast cancer patientsCancer patientsER-positive/HER2-negative tumorsBreast cancer molecular subtypesMETABRIC data setMolecular breast cancer subtypesCox regression analysisBreast cancer subtypesCancer molecular subtypesGene expression profilesMann-Whitney U testRegression analysisMultivariate regression analysisPrognostic valueKaplan-MeierBreast cancerClinical dataDisease outcomeTCGA cohortGene expressionMolecular subtypesCancer-associated genesCancer-related genesClinical relevance
2007
Gene-expression microarrays provide new prognostic and predictive tests for breast cancer
Gong Y, Symmans WF, Pusztai L. Gene-expression microarrays provide new prognostic and predictive tests for breast cancer. Pharmacogenomics 2007, 8: 1359-1368. PMID: 17979510, DOI: 10.2217/14622416.8.10.1359.Peer-Reviewed Original ResearchConceptsBreast cancerSystemic therapySpecific systemic therapySystemic therapy agentsGene expression microarraysBreast cancer researchProbability of responseTherapeutic regimensClinicopathologic variablesNecessary therapyDisease outcomeIndividual patientsAccurate markerClinical decisionIndividual tumorsCancerPredictive indicatorTherapyPredictive testIndividual basisPatientsCancer researchTherapy agentsMolecular differencesRecent progression
2004
Targeted Therapy in Breast Cancer The HER-2/neu Gene and Protein
Ross JS, Fletcher JA, Bloom KJ, Linette GP, Stec J, Symmans WF, Pusztai L, Hortobagyi GN. Targeted Therapy in Breast Cancer The HER-2/neu Gene and Protein. Molecular & Cellular Proteomics 2004, 3: 379-398. PMID: 14762215, DOI: 10.1074/mcp.r400001-mcp200.Peer-Reviewed Original ResearchConceptsBreast cancerNeu statusHormonal therapyAdvanced metastatic breast cancerHER-2/neu oncogeneHER-2/neu statusNew hormonal therapiesSerum-based testingMale breast cancerMetastatic breast cancerBreast cancer specimensClinical breast cancer specimensNeu gene amplificationEpidermal growth factor receptorTransmembrane tyrosine kinase receptorPrediction of responseGrowth factor receptorTyrosine kinase receptorsTrastuzumab therapyDuctal carcinomaNeu overexpressionHER-2Targeted therapyTumor cytosolsDisease outcome
2003
The HER-2/neu Gene and Protein in Breast Cancer 2003: Biomarker and Target of Therapy
Ross JS, Fletcher JA, Linette GP, Stec J, Clark E, Ayers M, Symmans WF, Pusztai L, Bloom KJ. The HER-2/neu Gene and Protein in Breast Cancer 2003: Biomarker and Target of Therapy. The Oncologist 2003, 8: 307-325. PMID: 12897328, DOI: 10.1634/theoncologist.8-4-307.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge DistributionAgedAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedBiomarkers, TumorBreast NeoplasmsBreast Neoplasms, MaleCombined Modality TherapyEducation, Medical, ContinuingFemaleGene Expression Regulation, NeoplasticGenes, erbB-2Genetic Predisposition to DiseaseHumansIncidenceMaleMiddle AgedNeoplasm StagingPrognosisRisk AssessmentSensitivity and SpecificitySurvival AnalysisTrastuzumabTreatment OutcomeConceptsBreast cancerHER-2/neu statusHER-2/neu oncogeneNeu geneNew hormonal therapiesSerum-based testingMale breast cancerHER-2/neu geneTarget of therapyNeu gene amplificationEpidermal growth factor receptorTransmembrane tyrosine kinase receptorPrediction of responseGrowth factor receptorHormonal therapyTyrosine kinase receptorsTrastuzumab therapyDuctal carcinomaNeu overexpressionHER-2Disease outcomeTumor cytosolsTherapy responseNeu statusNeu testing